Cancer immunotherapy can induce long lasting responses in patients with metastatic
cancers of a wide range of histologies. Broadening the clinical applicability of these …

The emergence of immune checkpoint blockade therapies over the last decade has
transformed cancer treatment in a wide range of tumor types. Unprecedented and durable …

Cancer immunotherapy utilizing blockade of the PD-1/PD-L1 checkpoint has revolutionized
the treatment of a wide variety of malignancies, leading to durable therapeutic responses not …

PD-1 immune checkpoint blockade provides significant clinical benefits for melanoma
patients. We analyzed the somatic mutanomes and transcriptomes of pretreatment …

Background Approximately 75% of objective responses to anti–programmed death 1 (PD-1)
therapy in patients with melanoma are durable, lasting for years, but delayed relapses have …

Summary PD-L1 and PD-L2 are ligands for the PD-1 immune inhibiting checkpoint that can
be induced in tumors by interferon exposure, leading to immune evasion. This process is …

Background Whether pembrolizumab given both before surgery (neoadjuvant therapy) and
after surgery (adjuvant therapy), as compared with pembrolizumab given as adjuvant …

Loss-of-function mutations in JAK1/2 can lead to acquired resistance to anti-programmed
death protein 1 (PD-1) therapy. We reasoned that they may also be involved in primary …

The development of effective, systemic therapies for metastatic cancer is highly desired. We
show here that the systemic delivery of sequence-specific small interfering RNA (siRNA) …

Neoantigens arise from mutations in cancer cells and are important targets of T cell-
mediated anti-tumor immunity. Here, we report the first open-label, phase Ib clinical trial of a …